DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Continued Examination Under 37 CFR 1.114
A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 3 March 2026 has been entered.
Claim Status
Applicant’s remarks and amendments, filed 11 February 2026 in response to the final rejection mailed 23 December 2025, are acknowledged and have been fully considered. Applicant’s amendments to the claims are acknowledged. The listing of claims filed 11 February 2026 replaces all prior versions and listings of the claims.
Claims 1, 3-15, 18, and 19 are pending. Claims 2, 16, and 17 are canceled by Applicant’s amendment. Claim 1 is amended. Claims 1, 3-15, 18, and 19 are being examined on the merits.
Information Disclosure Statement
The listing of references on pages 6-7 of the response filed 11 February 2026 is not a proper information disclosure statement (IDS). 37 CFR 1.98(b) requires a list of all patents, publications, or other information submitted for consideration by the Office, and MPEP § 609.04(a) states, "the list may not be incorporated into the specification but must be submitted in a separate paper." Therefore, unless the references have been cited by the examiner on form PTO-892 or listed on an IDS (or equivalent listing), they have not been considered.
Claim Rejections - 35 USC § 102/103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
Claims 1, 3-15, 18, and 19 are rejected under 35 U.S.C. 102(a)(1) as anticipated by or, in the alternative, under 35 U.S.C. 103 as obvious over Xu (US 2003/0021850 A1).
MPEP § 2112 provides guidance as to the Examiner' s burden of proof for a rejection of claims under 35 U.S.C. 102 or 103 based upon the express, implicit, and inherent disclosures of a prior art reference. The case law clearly states that something which is old does not become patentable upon the discovery of a new property.
The instant claims are as of record, drawn to a method for regulating the expression of Musashi 1 in cells comprising exposing mammalian cells to a regulating composition.
Xu teaches compositions and methods for promoting cell growth, tissue repair, and organ regeneration in vivo and in situ wherein the composition comprises a sterol, a fatty-acid containing oil (vegetable or animal oil), beeswax, and baicalin (Xu, [0024]-[0030], [0051], page 5; as required for instant Claim 1). The sterol is present dissolved in a fatty-acid containing oil in a concentration of 0.5 to 40 wt% (Xu, [0026], page 3) and can be a combination of stigmasterol, β-sitosterol, and brassicalsterol (Xu, [0046], page 4; as required for instant Claims 1, 12, 15 and 19). The fatty-acid containing oil can be a vegetable oil such as corn oil, peanut oil, safflower oil, sesame oil, olive oil, or soybean oil (Xu, [0042], page 4; as required for instant Claim 1 and 18). The beeswax is present at a concentration ranging from 1 to 20 wt% (Xu, [0070], page 6) and baicalin at a concentration ranging from 0.001 to 2 wt% (Xu, [0105], page 7; as required for instant Claims 1 and 12).
The composition is administered at the site of a dysfunctional tissue or organ of an adult mammal (exposing mammalian cells) wherein the dysfunctional tissue resulted from physical trauma (mechanically injured skin cells), a thermal injury (e.g., burn, see [0263]), or due to a diabetic ulcer and wherein the tissues can be skin (skin cells; epidermal cells; Xu, [0073]-[0080], page 6; as required for instant Claim 1). Physiologically functional tissues and organs such as skin can thus be regenerated (promotion) at the site of injury (Xu, [0080], page 6; as required for instant Claim 1) when applied for 15 to 30 days (at least 10 days; Xu, [0162], page 9; [0191], page 10; as required for instant Claims 1 and 11). The composition can also be used for culturing isolated mouse skin cells in vitro (Xu, [0572], page 39; as required for instant Claim 10).
The composition can further comprise propolis at a concentration from 0.1 to 30 wt% (Xu, [0430], page 28); obaculatone at a concentration from 0.1 to 2 wt% (Xu, [0053], page 6); obabenine (obaberine) at a concentration from 0.001 to 2 wt% (Xu, [0055], page 6); berberine at a concentration from 0.001 to 2 wt% (Xu, [0459], page 31); papaverine (Xu, [0475], page 32); and an extract of earthworm at a concentration from 2 to 60 wt% (Xu, [0061]-[0062], page 5; as required for instant Claim 3). The papaverine is extracted from dry capsules of poppy and the composition can be substantially free of papaverine, which is described as less than 0.01% and falls within the claimed ranges of 0.001 to 2 wt%; 0.002 to 0.5 wt%; and 0.003 to 0.1 wt% (Xu, [0475]-[0476], page 32; Claim 42, page 43; as required for instant Claims 3, 13, and 14).
Although Xu teaches each of the active steps in the claimed method, they are silent regarding the intended use of the method recited in the preamble i.e. regulating the expression of Musashi 1 in cells. The Patent and Trademark Office is not equipped to conduct experimentation in order to determine the mechanism of action resulting from cell exposure to a composition. The single-step method of exposing mammalian cells to a composition for a given duration of time is the same in both the prior art and instant application as described above, and thus the properties of regulating the expression of Musashi 1 (Claims 1 and 4) are inherent, especially in the absence of evidence to the contrary. See MPEP §§ 2112-2112.02.
The cited art taken as a whole demonstrates a reasonable probability that the method is either identical or sufficiently similar to the claimed method that whatever differences exist, they are not patentably significant.
The cited reference discloses a composition identical to that of the claimed invention which is applied to the same cell types for the same duration of time and thus appears to be identical to the presently claimed method since it is formulated and/or obtained from the same component materials and is administered/administrable to a mammalian cells. Consequently, the claimed process (and compositions provided therein) appears to be anticipated by the reference. In the alternative, even if the process (and compositions therein (with respect to an intended therapeutic effect of regulating the expression of Musashi 1) is not identical to the referenced process, with regard to some unidentified characteristics, the differences between that which is claimed and that which is disclosed, is so slight that the referenced composition is likely to inherently possess the same characteristics of in the claimed process, particularly in view of the similar characteristics which they have been shown to share (e.g. the similar component materials/formulations and the same broad administration). Thus, the claimed process (and administered-composition effects intrinsic thereto) would have at least been obvious to those of ordinary skill in the art within the meaning of 35 USC § 103(a).
Accordingly, the claimed invention as a whole was at least prima facie obvious, if not anticipated by the reference, especially in the absence of sufficient, clear, and convincing evidence to the contrary.
Please note, since the Office does not have the facilities for examining and comparing Applicants’ composition with the composition of the prior art (including compositions within the processes thereof), the burden is on applicant to show a novel or unobvious difference between the claimed product and the product of the prior art. See In re Best, 562 F.2d 1252, 195 USPQ 430 (CCPA 1977) and In re Fitzgerald, 619 F.2d 67, 205 USPQ 594 (CCPA 1980), and “as a practical matter, the Patent Office is not equipped to manufacture products by the myriad of processes put before it and then obtain prior art products and make physical comparisons therewith.” In re Brown, 459 F.2d 531, 535, 173 USPQ 685, 688 (CCPA 1972).
Response to Arguments
Applicant's arguments filed 11 February 2026 have been fully considered but they are not persuasive.
Applicant argues that regulation of Musashi 1 expression in skin cells is an unexpected finding resulting from the application of the claimed composition and that this differs from the prior art because the prior art discusses the effect of the composition on stem cells and does not disclose its use on skin cells.
This argument is not persuasive, because the same composition is administered at the site of a dysfunctional tissue or organ of an adult mammal (exposing mammalian cells) wherein the dysfunctional tissue resulted from physical trauma (mechanically injured skin cells), a thermal injury (e.g., burn, see [0263]), or due to a diabetic ulcer and wherein the tissues can be skin (skin cells; epidermal cells; Xu, [0073]-[0080], page 6). Physiologically functional tissues and organs such as skin can thus be regenerated (promotion) at the site of injury (Xu, [0080], page 6) when applied for 15 to 30 days (at least 10 days; Xu, [0162], page 9; [0191], page 10). Additionally, it is noted that in Example 3, the composition of Xu ([0584], page 39) is applied to surface ulcers on the lower limb of diabetic patients (e.g., applied directly to the skin of a patient with diabetic skin ulcers). This is identical to the test example in the instant disclosure (see e.g., page 8) wherein the instantly claimed composition is applied to diabetic foot ulcers. It is therefore unclear (i.e. Applicant’s arguments are not found to be persuasive or resolving of) how application of the same composition to the skin for the same type of injury would result in increased expression of Musashi 1 in one case but not the other, simply because Xu did not measure expression of that particular gene. Identifying differential expression of genes upon administration of the same composition to the same tissue for the same types of injuries is merely identification of inherent properties resulting from the application of said composition to said tissues for said injuries. See MPEP §§ 2112-2112.02.
Applicant additionally argues that their claims are drawn to regulating gene expression under specific scenarios rather than administration of a composition to specific tissues or organs in an animal, however it is again unclear how this differs from the prior art, wherein the same composition is applied under the same specific scenario of a diabetic ulcer. Discussing alternative uses, e.g., for culturing stem cells, does not preclude the composition from Xu, when applied to the skin for the same types of injuries as the instant disclosure, from also having the effect of increasing expression of Musashi 1 merely because it was not measured.
Finally, the applicant argues that because Musashi 1 is highly expressed in stem cells, a skilled artisan would not be motivated to further increase its expression. Again, the composition of Xu, which is the same as the composition of the instant claims as disclosed in the rejection above, was applied to the skin for the same types of injuries as the instant disclosure; it was not only applied to stem cells (see e.g., Xu, [0572]; [0580]; [0584]; [0586]; and [0588]).
Accordingly, the claimed invention as a whole was at least prima facie obvious, if not anticipated by the reference, especially in the absence of sufficient, clear, and convincing evidence to the contrary.
Conclusion
No claims are currently allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to JENNIFER L CAIN whose telephone number is (703)756-1318. The examiner can normally be reached M-Th 11:00am to 5:00pm EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anand Desai can be reached at (571)272-0947. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/J.L.C./Examiner, Art Unit 1655
/AARON J KOSAR/Primary Examiner, Art Unit 1655